Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Recro Pharma Inc (NQ: REPH )

3.217 USD -0.133 (-3.97%)
Streaming Delayed Price Updated: 9:30 AM EST, Jan 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Recro Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Recro Grants Inducement Award to New Chief Executive Officer
From GlobeNewswire News Releases
Recro Announces Executive Changes
David Enloe Named President and Chief Executive Officer 
From GlobeNewswire News Releases
Recro Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Recro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
Conference Call and Webcast Scheduled for Monday, November 9, 2020 at 8:00 a.m. ET 
From GlobeNewswire News Releases
Recro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
From GlobeNewswire News Releases
Recro Reports Second Quarter 2020 Financial Results
From GlobeNewswire News Releases
Recro to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
Conference Call and Webcast Scheduled for Monday, August 10, 2020 at 8:00 a.m. ET 
From GlobeNewswire News Releases
Recro Highlights Manufacturing Readiness For Essential Drugs and Medical Supplies
From GlobeNewswire News Releases
RECRO PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating Recro Pharma, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Recro Pharma, Inc. (NASDAQ: REPH) on behalf of Recro Pharma stockholders. Our... 
From Business Wire News Releases
INVESTOR ALERT: Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Recro Pharma, Inc.
From GlobeNewswire News Releases
Recro Pharma, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton; Investors Who Lost Money Should Contact the Firm
From GlobeNewswire News Releases
Investor Alert: Kaplan Fox Investigates Recro Pharma, Inc.
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Recro Pharma, Inc. ("Recro Pharma" or the "Company") (NASDAQ: REPH). Investors who purchased Recro... 
From PR Newswire
Recro Reports First Quarter 2020 Financial Results and Provides Update on COVID-19 Response and Impact
From GlobeNewswire News Releases
Recro to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 11, 2020
Conference Call and Webcast Scheduled for Monday, May 11, 2020 at 8:00 a.m. ET 
From GlobeNewswire News Releases
Recro Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters
From GlobeNewswire News Releases
Recro Reports Financial Results for the Year Ended 2019
From GlobeNewswire News Releases
Recro to Report Year End 2019 Financial Results and Host Conference Call and Webcast on March 4, 2020
Conference Call and Webcast Scheduled for Wednesday, March 4, 2020 at 8:00 a.m. ET 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Recro Pharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of... 
From PR Newswire
Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization
From GlobeNewswire News Releases
Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies
From GlobeNewswire News Releases
Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement
From GlobeNewswire News Releases
Recro Pharma Reports Third Quarter 2019 Financial Results
From GlobeNewswire News Releases
Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019
Conference Call and Webcast Scheduled for Friday, November 8, 2019 at 8:00 a.m. ET 
From GlobeNewswire News Releases
Recro Pharma’s Board of Directors Approves Separation of Acute Care Business Segment and Declares Special Dividend Distribution of Baudax Bio Common Stock
From GlobeNewswire News Releases
FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application
From GlobeNewswire News Releases
Recro Pharma Reports Second Quarter 2019 Financial Results
From GlobeNewswire News Releases
Recro Pharma to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
Conference Call and Webcast Scheduled for Thursday, August 8, 2019 at 8:00 a.m. ET 
From GlobeNewswire News Releases
Recro Pharma to Present at Upcoming Investor Conferences
Recro Pharma, Inc. (Nasdaq:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today announced that Gerri... 
From GlobeNewswire News Releases
Recro Pharma Reports First Quarter 2019 Financial Results
Company to Host Conference Call Today at 8:00 AM ET 
From GlobeNewswire News Releases
Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019
Conference Call and Webcast Scheduled for Friday, May 10, 2019 at 8:00 a.m. ET 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.